DE-PRESCRIBING MEDICATIONS IN OLDER ADULTS WITH DEMENTIA
Dr Daniel Hoyle
Senior Lecturer, Therapeutics and Pharmacy Practice
School of Pharmacy and Pharmacology,
University of Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | January 2025
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
He earned his PhD from the University of Tasmania in 2020, where his doctoral research examined the clinical and economic outcomes of psychotropic deprescribing within the multidisciplinary “Reducing Use of Sedatives” project implemented across 150 Australian aged care homes. This research has received several accolades, including First Place in the International Psychogeriatric Association Junior Research Awards in 2019.
Currently, Dr. Hoyle leads several projects, including research aimed at improving anticoagulant use in older individuals with dementia and atrial fibrillation using national primary care provider datasets, and the implementation of a hospital-based antipsychotic stewardship program for patients with dementia and/or delirium.
A current project is Geriatric Antipsychotic Stewardship (GApS) Program for Behavioural and Psychological Symptoms of Dementia and Delirium. This program is funded by the Royal Hobart Hospital Research Foundation through an Incubator Grant.
Additionally, Dr. Hoyle serves as an investigator within an educational intervention aimed at improving anticholinergic prescribing in hospitals. Dr. Hoyle is a guest editor with Pharmacy MDPI and holds elected positions on the Australian Deprescribing Network Executive Committee and the Pharmaceutical Society of Australia’s Tasmanian Branch Committee.
https://orcid.org/0000-0003-2867-3736
-
CASE STUDY High blood pressure and shorter sleep may worsen brain decline
People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.
Published in the Journal of the American Heart Association, researchers assessed whether the combined effect of hypertension and short sleep duration had a negative impact on brain health.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
